Next Article in Journal
Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins
Previous Article in Journal
HIV Genetic Diversity and Drug Resistance
Previous Article in Special Issue
RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis
Viruses 2010, 2(2), 532-546; doi:10.3390/v2020532
Review

Developing Vaccines to Combat Pandemic Influenza

*  and
Received: 25 November 2009 / Revised: 28 January 2010 / Accepted: 29 January 2010 / Published: 2 February 2010
(This article belongs to the Special Issue Influenza: Pandemics and Vaccinations)
View Full-Text   |   Download PDF [202 KB, uploaded 12 May 2015]   |   Browse Figures

Abstract

Influenza vaccine manufacturers require antigenically relevant vaccine viruses that have good manufacturing properties and are safe to use. In developing pandemic vaccine viruses, reverse genetics has been employed as a rational approach that can also be used effectively to attenuate the highly virulent H5N1 virus and at the same time place the H5 HA and N1 NA on a background of PR8, a virus that has been used over many decades to provide high yielding vaccine viruses. Reverse genetics has also been used successfully alongside classical reassorting techniques in the development of (swine flu) pandemic A(H1N1)v vaccine viruses.
Keywords: pandemic influenza vaccines; reverse genetics; H5N1 virus; H1N1v virus pandemic influenza vaccines; reverse genetics; H5N1 virus; H1N1v virus
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Robertson, J.S.; Engelhardt, O.G. Developing Vaccines to Combat Pandemic Influenza. Viruses 2010, 2, 532-546.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert